• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Irene M. Ghobrial, MD


  • Patel CG, Yee AJ, Scullen TA, Nemani N, Santo L, Richardson PG, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Raje NS.Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy.Clin Cancer Res. 2014 Jun 23.
  • Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM.Engineered nanomedicine for myeloma and bone microenvironment targeting.Proc Natl Acad Sci U S A. 2014 Jun 30.
  • Zabora J, Buzaglo J, Kennedy V, Richards T, Schapmire T, Zebrack B, Ghobrial IM.Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma.Palliative & Supportive Care. 2014 Jun 24:1-10.
  • Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ.Carfilzomib, rituximab and dexamethasone (CaRD) is active and offers a neuropathy-sparing approach for proteasome-inhibitor based therapy in Waldenstrom's macroglobulinemia.Blood. 2014 May 23.
  • Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, Roccaro AM, Ghobrial IM.Role of endothelial progenitor cells in cancer progression.Biochim Biophys Acta. 2014 Apr 4;1846(1):26-39.
  • Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.British Journal of Haematology. 2014 Apr 25.
  • Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM.Regulation of microRNAs in cancer metastasis.Biochim Biophys Acta. 2014 Apr;1845(2):255-265.
  • Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O'Driscoll L.miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.Mol Cancer. 2014;13(1):71.
  • Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.Blood. 2014 Mar 6;123(10):1461-9.
  • Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, Aljawai Y, Sahin I, Kuhne M, Cardarelli P, Cohen L, San Miguel JF, Garcia-Sanz R, Ghobrial IM.C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.Blood. 2014 Apr 7.
  • Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, DeAngelo D, Treon SP.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Am J Hematol. 2014 Mar;89(3):237-42.
  • Sahin I, Leblebjian H, Treon SP, Ghobrial IM.Waldenström macroglobulinemia: from biology to treatment.Expert Rev Hematol. 2014 Feb;7(1):157-68.
  • Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM.Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.PLoS ONE. 2013;8(6):e66982.
  • Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM.BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.J Clin Invest. 2013 Apr 1;123(4):1542-55.
  • Ghobrial IM.Update on Waldenström's Macroglobulinemia.Clin Adv Hematol Oncol. 2013 Apr;11(4):244-6.
  • Ghobrial IM.Correspondence: Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new?.Leuk Lymphoma. 2013 Mar 30.
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.Blood. 2013 Mar 14;121(11):1961-7.
  • Sacco A, Zhang Y, Maiso P, Manier S, Rossi G, Treon SP, Ghobrial IM, Roccaro AM.microRNA Aberrations in Waldenström Macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2013 Mar 6.
  • Agarwal A, Ghobrial IM.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Clin Cancer Res. 2013 Mar 1;19(5):985-94.
  • Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Blood. 2013 Feb 21;121(8):1296-303.
  • Ghobrial IM.Choice of therapy for patients with Waldenstrom macroglobulinemia.J Clin Oncol. 2013 Jan 20;31(3):291-3.
  • Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P.Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.British Journal of Haematology. 2013 Feb;160(3):351-8.
  • Weinstock M, Ghobrial IM.Extramedullary multiple myeloma.Leuk Lymphoma. 2012 Dec 31.
  • Ghobrial IM.Are you sure this is Waldenstrom macroglobulinemia?.Hematology Am Soc Hematol Educ Program. 2012;2012:586-94.
  • Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP.Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.British Journal of Haematology. 2012 Nov 15.
  • Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM.Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia.Clin Cancer Res. 2012 Nov 14.
  • Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL.Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.J Breast Cancer. 2012 Sep;15(3):273-82.
  • Bianchi G, Ghobrial IM.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Leuk Lymphoma. 2012 Sep 17.
  • Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Leblond V.A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.Clin Cancer Res. 2012 Sep 15;18(18):5043-50.
  • Maiso P, Ghobrial IM.Would the real myeloma cell please stand up?.Leuk Lymphoma. 2012 Oct;53(10):1851-2.
  • Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM.LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.Blood. 2012 Aug 23;120(8):1678-86.
  • Ghobrial IM.Myeloma as a model for the process of metastasis: implications for therapy.Blood. 2012 Jul 5;120(1):20-30.
  • Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM.Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia.Clin Cancer Res. 2011 Apr 1;17(7):1753-64.
  • Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM.Key Role of MicroRNAs in Waldenström's Macroglobulinemia Pathogenesis.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):109-11.
  • Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, Roccaro A.The Bone Marrow Niche in Waldenström's Macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):118-20.
  • Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM.Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):164-7.
  • Leleu XP, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N, Weller E, Ghobrial IM.The Role of Serum Immunoglobulin Free Light Chain (sFLC) in response and progression in Waldenstrom Macroglobulinemia (WM).Clin Cancer Res. 2011 Mar 17.
  • Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.Lancet Oncol. 2011 Mar;12(3):263-72.
  • Sacco A, Roccaro A, Ghobrial IM.Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.Oncotarget. 2010 Nov;1(7):578-82.
  • Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP.Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.J Biomed Opt.;16(1):011006.
  • Calvo KR, Landgren O, Roccaro AM, Ghobrial IM.Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma.Semin Hematol. 2011 Jan;48(1):39-45.
  • Roper N, Deangelo DJ, Kuo F, Cin PD, Ghobrial I, Aster JC.An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma.Am J Hematol. 2010 Dec;85(12):944-6.
  • Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, Roccaro AM.Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology.J Hematol Oncol. 2010;3(1):38.
  • Rourke M, Anderson KC, Ghobrial IM.Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.Leuk Lymphoma. 2010 Oct;51(10):1779-92.
  • Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.Am J Hematol. 2010 Sep;85(9):670-4.
  • Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM.microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.Blood. 2010 Sep 2;116(9):1506-14.
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
  • Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC.Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.Blood. 2010 Jul 1;115(26):5385-92.
  • Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K.Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.Oncology (Huntingt). 2010 Mar;24(3 Suppl 2):22-9.
  • Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM.Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.Blood. 2010 May 20;115(20):4051-60.
  • Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.J Clin Oncol. 2010 Mar 10;28(8):1422-8.
  • Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.J Clin Oncol. 2010 Mar 10;28(8):1408-14.
  • Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.Clin Cancer Res. 2010 Feb 1;16(3):1033-41.
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4.
  • Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM.Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.Blood. 2010 Jan 21;115(3):559-69.
  • Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia..
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.J Clin Oncol. 2009 Dec 1;27(34):5713-9.
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw..
  • Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM.Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.Clin Cancer Res. 2009 Oct 1;15(19):6035-41.
  • Venon MD, Roccaro AM, Gay J, Moreau AS, Dulery R, Facon T, Ghobrial IM, Leleu X.Front line treatment of elderly multiple myeloma in the era of novel agents.Biologics. 2009;3:99-109.
  • Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM.Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.J Clin Oncol. 2009 Aug 10;27(23):3830-5.
  • Azab AK,Azab F,Blotta S,Pitsillides CM,Thompson B,Runnels JM,Roccaro AM,Ngo HT,Melhem MR,Sacco A,Jia X,Anderson KC,Lin CP,Rollins BJ,Ghobrial IM.Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma.Blood. 2009 Jul 16;114(3):619-29.
  • Roccaro AM,Sacco A,Thompson B,Leleu X,Azab AK,Azab F,Runnels J,Jia X,Ngo HT,Melhem MR,Lin CP,Ribatti D,Rollins BJ,Witzig TE,Anderson KC,Ghobrial IM.microRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.Blood. 2009 Jun 25;113(26):6669-80.
  • Laubach JP,Mitsiades CS,Roccaro AM,Ghobrial IM,Anderson KC,Richardson PG.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia.Leuk Lymphoma. 2009 May;50(5):694-702. Review.
  • Braggio E,Keats JJ,Leleu X,Wier SV,Jimenez-Zepeda VH,Schop RF,Chesi M,Barrett M,Stewart AK,Dogan A,Bergsagel PL,Ghobrial IM,Fonseca R.High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.Clin Lymphoma Myeloma. 2009 Mar;9(1):39-42.
  • Leleu X,Tamburini J,Roccaro A,Morel P,Soumerai J,Levy V,Wemeau M,Balkaran S,Poulain S,Hunter ZR,Ghobrial IM,Treon SP,Leblond V.Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy.Clin Lymphoma Myeloma. 2009 Mar;9(1):71-3.
  • Roccaro AM,Sacco A,Leleu X,Azab AK,Azab F,Runnels J,Jia X,Ngo HT,Melhem M,Moreau AS,Ghobrial IM.Role of proteasome inhibition in Waldenstrom's macroglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):94-6. Review.
  • Ghobrial IM,Leleu X,Azab AK,Runnels J,Jia X,Ngo H,Melhem M,Azab F,Sacco A,Quang P,Burwick N,Moreau AS,Husu E,Farag M,Roccaro A.Novel therapeutic agents in Waldenstrom's macroglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):84-6. Review.
  • Braggio E,Keats JJ,Leleu X,Van Wier S,Jimenez-Zepeda VH,Valdez R,Schop RF,Price-Troska T,Henderson K,Sacco A,Azab F,Greipp P,Gertz M,Hayman S,Rajkumar SV,Carpten J,Chesi M,Barrett M,Stewart AK,Dogan A,Bergsagel PL,Ghobrial IM,Fonseca R.Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.Cancer Res. 2009 Apr 15;69(8):3579-88.
  • Leleu X,Hunter ZR,Xu L,Roccaro AM,Moreau AS,Santos DD,Hatjiharissi E,Bakthavachalam V,Adamia S,Ho AW,Soumerai J,Patterson CJ,Manning RJ,Hamilton S,Verselis S,Fox E,Carrasco R,Ghobrial IM,Treon SP.Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.British Journal of Haematology. 2009 Apr;145(1):59-63.
  • Azab AK,Runnels JM,Pitsillides C,Moreau AS,Azab F,Leleu X,Jia X,Wright R,Ospina B,Carlson AL,Alt C,Burwick N,Roccaro AM,Ngo HT,Farag M,Melhem MR,Sacco A,Munshi NC,Hideshima T,Rollins BJ,Anderson KC,Kung AL,Lin CP,Ghobrial IM.CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.Blood. 2009 Apr 30;113(18):4341-51.
  • Leleu X,Gay J,Roccaro AM,Moreau AS,Poulain S,Dulery R,Champs BB,Robu D,Ghobrial IM.Update on therapeutic options in Waldenstrom macroglobulinemia.Eur J Haematol. 2009 Jan;82(1):1-12. Review.
  • Roccaro AM,Sacco A,Chen C,Runnels J,Leleu X,Azab F,Azab AK,Jia X,Ngo HT,Melhem MR,Burwick N,Varticovski L,Novina CD,Rollins BJ,Anderson KC,Ghobrial IM.microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia.Blood. 2009 Apr 30;113(18):4391-402.
  • Leleu X,Soumerai J,Roccaro A,Hatjiharissi E,Hunter ZR,Manning R,Ciccarelli BT,Sacco A,Ioakimidis L,Adamia S,Moreau AS,Patterson CJ,Ghobrial IM,Treon SP.Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs.J Clin Oncol. 2009 Jan 10;27(2):250-5.
  • Dimopoulos MA,Gertz MA,Kastritis E,Garcia-Sanz R,Kimby EK,Leblond V,Fermand JP,Merlini G,Morel P,Morra E,Ocio EM,Owen R,Ghobrial IM,Seymour J,Kyle RA,Treon SP.Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.J Clin Oncol. 2009 Jan 1;27(1):120-6. Review.
  • Leleu X,Xu L,Jia X,Sacco A,Farag M,Hunter ZR,Moreau AS,Ngo HT,Hatjiharissi E,Ho AW,Santos DD,Adamia S,O'Connor K,Ciccarelli B,Soumerai J,Manning RJ,Patterson CJ,Roccaro AM,Ghobrial IM,Treon SP.Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.Blood. 2009 Jan 15;113(3):626-34.
  • Oton AB,Wang H,Leleu X,Melhem MF,George D,Lacasce A,Foon K,Ghobrial IM.Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant.Leuk Lymphoma. 2008 Sep;49(9):1738-44.
  • Richardson PG,Mitsiades C,Schlossman R,Ghobrial I,Hideshima T,Munshi N,Anderson KC.Bortezomib in the front-line treatment of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. Review.
  • Alsayed Y,Leleu X,Leontovich A,Oton AB,Melhem M,George D,Ghobrial IM.Proteomics analysis in post-transplant lymphoproliferative disorders.Eur J Haematol. 2008 Oct;81(4):298-303.
  • Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM.SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom Macroglobulinemia.Blood. 2008 Jul 1;112(1):150-8.
  • Leleu X,Roccaro AM,Moreau AS,Dupire S,Robu D,Gay J,Hatjiharissi E,Burwik N,Ghobrial IM.Waldenstrom macroglobulinemia.Cancer Lett. 2008 Oct 18;270(1):95-107.
  • Moreau AS,Jia X,Patterson CJ,Roccaro AM,Xu L,Sacco A,O'Connor K,Soumerai J,Ngo HT,Hatjiharissi E,Hunter ZR,Ciccarelli B,Manning R,Ghobrial IM,Leleu X,Treon SP.The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.British Journal of Haematology. 2008 Sep;142(5):775-85.
  • Burwick N,Roccaro AM,Leleu X,Ghobrial IM.Targeted therapies in Waldenstrom macroglobulinemia.Curr Opin Investig Drugs. 2008 Jun;9(6):631-7. Review.
  • Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Friec GL, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X.Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.Eur J Haematol. 2008 Jun;80(6):503-9.
  • Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM.Targeting NF-{kappa}B in Waldenstrom macroglobulinemia.Blood. 2008 May 15;111(10):5068-77.
  • Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM.Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.Leuk Lymphoma. 2008 Apr 23:1-4.
  • Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM.Dual targeting of the proteasome regulates survival and homing in Waldenstrom's Macroglobulinemia.Blood. 2008 May 1;111(9):4752-63.
  • Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP.Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom's macroglobulinemia.Clin Cancer Res. 2008 Mar 15;14(6):1849-58.
  • Krim S, Vivo R, Ghobrial I, Ergina F.Misplaced concern.Am J Med. 2008 Mar;121(3):196-8.
  • Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM.Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.Clin Cancer Res. 2008 Feb 1;14(3):865-74.
  • Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K.The treatment of relapsed and refractory multiple myeloma.Hematology Am Soc Hematol Educ Program. 2007;2007:317-23. Review.
  • Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I.Novel agents in the treatment of Waldenstrom's macroglobulinemia.Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S199-206. Review.
  • Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM.The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.Blood. 2007 Dec 15;110(13):4417-26.
  • Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P.Novel therapeutic avenues in myeloma: changing the treatment paradigm.Oncology (Huntingt). 2007 Jun;21(7):785-92; discussion 798-800. Review.
  • Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC.Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis.Blood. 2007 Sep 1;110(5):1656-63.
  • Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM.Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.Clin Cancer Res. 2007 Jul 1;13(13):3771-5. Review.
  • Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM.Proteomic analysis of waldenstrom macroglobulinemia.Cancer Res. 2007 Apr 15;67(8):3777-84.
  • Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P.Emerging drugs in multiple myeloma.Expert Opin Emerg Drugs. 2007 Mar;12(1):155-63. Review.
  • Moreau AS, Jia X, Ngo HT, Leleu X, O'sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM.Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.Blood. 2007 Jun 1;109(11):4964-72.
  • Hwang JJ, Ghobrial IM, Anderson KC.New frontiers in the treatment of multiple myeloma.ScientificWorldJournal. 2006;6:1475-503. Review.
  • Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.Clin Cancer Res. 2006 Nov 15;12(22):6826-35.
  • Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Ct D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM.Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.Blood. 2007 Apr 1;109(7):2708-17.
  • Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I, Raje N, Munshi N, Anderson KC.A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.Oncogene. 2007 Apr 5;26(16):2374-80.
  • Richardson PG, Mitsiades C, Ghobrial I, Anderson K.Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.Curr Opin Oncol. 2006 Nov;18(6):598-608. Review.